{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-054312","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.824683+00:00","generated_at":"2026-06-05T05:44:50.508060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Biosciences Q4 revenue up 21% to $58.6M; full year net loss $11.3M; guides 5-10% growth for 2024","bullets":["Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).","Q4 net income $6.3M vs $3.7M; full year net loss $11.3M vs income $2.5M.","2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income.","Repurchased 5.3M shares for $34.7M in Q4; 6.6M total since May 2023.","Introduced Cytek Orion automated antibody cocktail prep system."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-054312","json":"https://secwatch.observer/filing/0001193125-24-054312.json","markdown":"https://secwatch.observer/filing/0001193125-24-054312.md","text":"https://secwatch.observer/filing/0001193125-24-054312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/d781057d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:44:50.508060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25db37945373271049f9bf9f06be10bec88d3fce","claim":"Cytek Biosciences, Inc. reported year ended December 31, 2023 results: revenue $193.4 million, net income $11.3 million.","evidence_excerpt":"the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 million • Total revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023, representing 18% and 13% increases, respectively, over the full year 2022. • Organic revenue was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$193.4 million"},{"label":"Net income","value":"$11.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"93a99fc6201a5a2bec3f9676900f422ecef8d7f6","claim":"Cytek Biosciences, Inc. reported fourth quarter ended December 31, 2023 results: revenue $58.6 million, net income $6.3 million.","evidence_excerpt":"CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights • Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$58.6 million"},{"label":"Net income","value":"$6.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}